Abstract 7319: Targeting HDAC1 activity presents vulnerabilities in pancreatic cancer metabolism

Abstract Pancreatic cancer is a lethal disease with significant metabolic reprogramming, which promotes tumor growth, therapy resistance, and adaptation to stress. These alterations are largely attributed to mutations in the KRAS oncogene but with limited progress in therapeutic discovery. Despite the recent focus on metabolism in pancreatic cancer, the major mediators of altered metabolism remain unknown. Our differential gene expression analyses in multiple patient cohorts’ pancreatic tumors versus normal tissues identify histone deacetylase 1 (HDAC1) as a consistently upregulated epigenetic gene. HDAC1-high tumors correlate strongly with metabolic pathways, including glycolysis, redox metabolism, and nucleotide biosynthesis. Using CRISPR/Cas9 gene editing, we found that the deletion of HDAC1 in pancreatic cancer cell lines triggers metabolic shifts, notably in glucose metabolism, and led to a distinct growth phenotype in a cell context-dependent manner. Similarly, treatment with class I selective HDAC inhibitors was selectively effective in suppressing pancreatic cancer cell growth. Furthermore, our drug screenings demonstrate profound synergies that overlap across the HDAC1-deleted and HDACi treated cell lines that present under-explored avenues for therapeutics. Our data provides evidence of compensatory metabolic alterations upon HDAC1 inhibition, which could broaden the opportunities for therapeutic intervention in pancreatic cancer. Citation Format: Don-Gerard C. Conde, Evan J. Zhou, Soren Jensen, Maximillian Farma, Chiamaka Joy Ezeh, Alexander N. Behram, Phuong T. Pham, Nabila N. Binti, Laiba Shiekh, Matthew C. Cheung, Zeribe Nwosu, . Targeting HDAC1 activity presents vulnerabilities in pancreatic cancer metabolism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7319.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-7319
Primary Topic
Histone Deacetylase Inhibitors Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 7319: Targeting HDAC1 activity presents vulnerabilities in pancreatic cancer metabolism

Don-Gerard Conde, Zeribe C. Nwosu, Laiba Shiekh, Chiamaka Joy Ezeh et al.
Cancer Research
Histone Deacetylase Inhibitors Research
article

Abstract 7319: Targeting HDAC1 activity presents vulnerabilities in pancreatic cancer metabolism

Don-Gerard Conde, Zeribe C. Nwosu, Laiba Shiekh, Chiamaka Joy Ezeh, Maximillian Farma, Evan J. Zhou, Alexander N. Behram, Nabila N. Binti, Phuong T. Pham, Soren Jensen
article en

Abstract

Abstract Pancreatic cancer is a lethal disease with significant metabolic reprogramming, which promotes tumor growth, therapy resistance, and adaptation to stress. These alterations are largely attributed to mutations in the KRAS oncogene but with limited progress in therapeutic discovery. Despite the recent focus on metabolism in pancreatic cancer, the major mediators of altered metabolism remain unknown. Our differential gene expression analyses in multiple patient cohorts’ pancreatic tumors versus normal tissues identify histone deacetylase 1 (HDAC1) as a consistently upregulated epigenetic gene. HDAC1-high tumors correlate strongly with metabolic pathways, including glycolysis, redox metabolism, and nucleotide biosynthesis. Using CRISPR/Cas9 gene editing, we found that the deletion of HDAC1 in pancreatic cancer cell lines triggers metabolic shifts, notably in glucose metabolism, and led to a distinct growth phenotype in a cell context-dependent manner. Similarly, treatment with class I selective HDAC inhibitors was selectively effective in suppressing pancreatic cancer cell growth. Furthermore, our drug screenings demonstrate profound synergies that overlap across the HDAC1-deleted and HDACi treated cell lines that present under-explored avenues for therapeutics. Our data provides evidence of compensatory metabolic alterations upon HDAC1 inhibition, which could broaden the opportunities for therapeutic intervention in pancreatic cancer. Citation Format: Don-Gerard C. Conde, Evan J. Zhou, Soren Jensen, Maximillian Farma, Chiamaka Joy Ezeh, Alexander N. Behram, Phuong T. Pham, Nabila N. Binti, Laiba Shiekh, Matthew C. Cheung, Zeribe Nwosu, . Targeting HDAC1 activity presents vulnerabilities in pancreatic cancer metabolism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7319.

Cancer ResearchVol. 86(7_Supplement)
Cornell University (US)
Good health and well-being
Openalex Percentile: Top 22%
Histone Deacetylase Inhibitors Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.